References
- Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 2015;4:36–54
- Luo SY, Lam DC. Oncogenic driver mutations in lung cancer. Transl Respir Med 2013;1:6
- Rothschild SI. Targeted therapies in non-small cell lung cancer—beyond EGFR and ALK. Cancers 2015;7:930–49
- Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016;387:1415–26
- Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998–2006
- Salgia R. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn 2016;16:737–49
- Aisner DL, Sholl LM, Berry L, et al. The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res 2017;24:1038-1047
- Luk PP, Yu B, Ng CC, et al. BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res 2015;4:142–8
- Khoo C, Rogers T-M, Fellowes A, et al. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Transl Lung Cancer Res 2015;4:126–41
- Daniels M, Goh F, Wright CM, et al. Whole genome sequencing for lung cancer. J Thorac Dis 2012;4:155–63
- Cronin M, Ross JS. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark Med 2011;5:293–305
- Popper HH, Tímár J, Ryska A, et al. Minimal requirements for the molecular testing of lung cancer. Transl Lung Cancer Res 2014;3:301–4
- Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011;22:2616-2624
- van Dijk EL, Auger H, Jaszczyszyn Y, et al. Ten years of next-generation sequencing technology. Trends Genet 2014;30:418–26
- Xuan J, Yu Y, Qing T, et al. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett 2013;340:284–95
- Kearney N, Miller M, Paul J, et al. Oncology healthcare professionals’ attitudes toward elderly people. Ann Oncol 2000;11:599–601
- Bouchardy C, Rapiti E, Blagojevic S, et al. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 2007;25:1858–69
- Penson RT, Daniels KJ, Lynch TJ Jr. Too old to care? Oncologist 2004;9:343–52
- FDA. TAFINLAR (dabrafenib) capsules for oral use. FDA; Silver Spring, MD. 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202806s006lbl.pdf
- National Comprehensive Cancer Network (NCCN). NCCN guidelines for non-small cell lung cancer v8.2017. NCCN; Fort Washington, PA. 2017. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx
- My Cancer Genome. Molecular profiling of lung cancer. Nashville, TN. 2016. Available at: https://www.mycancergenome.org/content/disease/lung-cancer/
- Clinicaltrials.gov. Cabozantinib in patients with RET fusion-positive advanced non-small cell lung cancer and those with other genotypes: ROS1 or NTRK fusions or increased MET or AXL activity. Bethesda, MD: U.S. National Library of Medicine. 2018. Available at: https://clinicaltrials.gov/ct2/show/NCT01639508
- Clinicaltrials.gov. Clinical study of oral cMET inhibitor INC280 in adult patients with advanced non-small cell lung cancer who have received one or two prior lines of therapy. Bethesda, MD: U.S. National Library of Medicine. 2018. Available at: https://clinicaltrials.gov/ct2/show/NCT02414139
- Clinicaltrials.gov. A trial of AP32788 in non-small cell lung cancer. Bethesda, MD: U.S. National Library of Medicine. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02716116
- American Cancer Society. Key statistics for lung cancer. ACS; Atlanta, GA. 2016. Available at: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics